Fostamatinib for the treatment of chronic immune thrombocytopenia

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

Rodeghiero, F., Stasi, R., Gernsheimer, T., Michel, M., Provan, D., Arnold, D. M., Bussel, J. B., Cines, D. B., Chong, B. H., Cooper, N., et al. (2008) · Blood · doi:10.1182/blood-2008-07-162503 · Cited by 2,699

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

Neunert, C. E., Lim, W., Crowther, M. A., Cohen, A. R., Solberg, L. A., & Crowther, M. A. (2011) · Blood · doi:10.1182/blood-2010-08-302984 · Cited by 1,853

Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications

Kojouri, K., Vesely, S. K., Terrell, D. R., et al. (2004) · Blood · doi:10.1182/blood-2004-03-1168 · Cited by 653

Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura

Arnold, D. M., Dentali, F., Crowther, M. A., Meyer, R. M., Cook, R. J., Sigouin, C. S., Fraser, G. A. M., Lim, W., & Kelton, J. G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-1-200701020-00006 · Cited by 551

R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation

Braselmann, S., Taylor, V., Zhao, H., Wang, S., Sylvain, C., Baluom, M., Qu, K., Herlaar, E., Lau, A., Young, C., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.109058 · Cited by 519

An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis

Weinblatt, M. E., Kavanaugh, A., Genovese, M. C., Musser, T. K., Grossbard, E. B., & Magilavy, D. B. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000500 · Cited by 386

Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials

Bussel, J. B., Arnold, D. M., Grossbard, E., Mayer, J., Treliński, J., Homenda, W., Hellmann, A., Windyga, J., Sivcheva, L., Khalafallah, A. A., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25125 · Cited by 378

Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia

Patel, V., Mahévas, M., Lee, S. Y., et al. (2012) · Blood · doi:10.1182/blood-2011-11-393975 · Cited by 349

Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up

Kristinsson, S. Y., Gridley, G., Hoover, R. N., Check, D. P., & Landgren, O. (2013) · Haematologica · doi:10.3324/haematol.2013.092460 · Cited by 347

Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study

Saleh, M. N., Bussel, J. B., Cheng, G. Y.-M., et al. (2012) · Blood · doi:10.1182/blood-2012-04-425512 · Cited by 338

Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy

Kuter, D. J., Bussel, J. B., Newland, A. C., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12260 · Cited by 276

Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk

Podolanczuk, A. J., Lazarus, A. H., Crow, A. R., Grossbard, E., & Bussel, J. B. (2008) · Blood · doi:10.1182/blood-2008-07-166439 · Cited by 264

Getting Syk: spleen tyrosine kinase as a therapeutic target

Geahlen, R. L. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.05.007 · Cited by 240

High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis

Mithoowani, S., Gregory-Miller, K., Goy, J., Miller, M. C., Wang, G., Noroozi, N., Kelton, J. G., & Arnold, D. M. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30109-0 · Cited by 186

How I treat refractory immune thrombocytopenia

Cuker, A. C., & Neunert, C. E. (2016) · Blood · doi:10.1182/blood-2016-03-603365 · Cited by 154

Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program

Khellaf, M., Michel, M., Quittet, P., et al. (2011) · Blood · doi:10.1182/blood-2011-03-340166 · Cited by 113

Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim

Cines, D. B., Gernsheimer, T., Wasser, J. S., et al. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1837-6 · Cited by 98

Metabolism of Fostamatinib, the Oral Methylene Phosphate Prodrug of the Spleen Tyrosine Kinase Inhibitor R406 in Humans: Contribution of Hepatic and Gut Bacterial Processes to the Overall Biotransformation

Sweeny, D. J., Li, W., Clough, J., Bhamidipati, S., Singh, R., Park, G., Baluom, M., Grossbard, E. B., & Lau, D. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032151 · Cited by 93

Short‐term and long‐term failure of laparoscopic splenectomy in adult immune thrombocytopenic purpura patients: A systematic review

Mikhael, J. R., Northridge, K., Lindquist, K. J., et al. (2009) · American Journal of Hematology · doi:10.1002/ajh.21501 · Cited by 88

Fostamatinib for Persistent/Chronic Adult Immune Thrombocytopenia

Newland, A. C., Lee, E., McDonald, V., & Bussel, J. B. (2017) · Immunotherapy · doi:10.2217/imt-2017-0097 · Cited by 77

Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters

Toltl, L. J., & Arnold, D. M. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08412.x · Cited by 54

Fostamatinib disodium

Tam, F. W. K., & McAdoo, S. P. (2011) · Drugs of the Future · doi:10.1358/dof.2011.036.04.1588554 · Cited by 51

The contribution of VEGF signalling to fostamatinib‐induced blood pressure elevation

Skinner, M. R., Philp, K. L., Lengel, D., Coverley, L. C., Bergström, E. L., Glaves, P. D., Musgrove, H. L., Prior, H. M., Braddock, M., Huby, R., et al. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12559 · Cited by 50

Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia

Janssens, A., Rodeghiero, F., Anderson, D. R., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2682-2 · Cited by 50

Syk-dependent signaling pathways in neutrophils and macrophages are indispensable in the pathogenesis of anti-collagen antibody-induced arthritis

Ozaki, N., Suzuki, S., Ishida, M., Harada, Y., Tanaka, K., Sato, Y., Kono, T., Kubo, M., Kitamura, D., Encinas, J., et al. (2012) · International Immunology · doi:10.1093/intimm/dxs078 · Cited by 49

Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies

Martin, P. D., Gillen, M. S., Ritter, J. M., Mathews, D. R., BREALEY, C. J., Surry, D. D., Oliver, S. D., Holmes, V., Severin, P., & Elsby, R. (2016) · Drugs in R&D · doi:10.1007/s40268-015-0120-x · Cited by 46

A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas

Park, S. R., Speranza, G., Piekarz, R., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2091-3 · Cited by 38

Primary immune thrombocytopenia: understanding pathogenesis is the key to better treatments

Chong, B. H. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03258.x · Cited by 18

Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program

Duliège, A., Arnold, D. M., Boccia, R. V., et al. (2018) · Blood · doi:10.1182/blood-2018-99-110482 · Cited by 11

ASGARD is a single-cell guided pipeline to aid repurposing of drugs

He, B., Xiao, Y., Liang, H., Huang, Q., Du, Y., Li, Y., Garmire, D., Sun, D., & Garmire, L. X. (2023) · Nature Communications · doi:10.1038/s41467-023-36637-3 · Cited by 57

Review article: THE ROLE OF ELTROMBOPAG AND ROMIPLOSTIM AS THE THROMBOPOIETIN RECEPTOR AGONIST (TPO-RA) IN TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP): WHAT IS TPO-RA, WHEN TPO-RA IS USED AND HOW TO TAKE TPO-RA?

Susanto, J. P. (2016) · Folia Medica Indonesiana · doi:10.20473/fmi.v51i3.2840 · Cited by 1

Thrombocytopenia in Patients With Myelodysplastic Syndromes

Bryan, J., Jabbour, E. J., Prescott, H., & Kantarjian, H. M. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.02.006 · Cited by 39

No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura

D'Arena, G. F., Guariglia, R., Mansueto, G., et al. (2013) · Blood · doi:10.1182/blood-2012-11-465575 · Cited by 23

New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents

Abrams, C. (2009) · Biologics · doi:10.2147/btt.s5578 · Cited by 9

The problem of immune thrombocytopenia refractory to both eltrombopag and romiplostim

Al-Samkari, H. T., Schifferli, A., & González‐López, T. J. (2024) · British Journal of Haematology · doi:10.1111/bjh.19327 · Cited by 5